TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22525762

Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel bid
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel tid
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel bid or tid
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: DDEA 2.32% gel
Number of subjects: 242
Study: 20186018

Group type: EXPERIMENTAL
Intervention: Energy healing modalities (Reiki, therapeutic touch, healing touch)
Number of subjects: 0
Study: 17512301

Group type: EXPERIMENTAL
Intervention: VR training until a predefined expert level of performance was reached
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 16271786

Group type: EXPERIMENTAL
Intervention: 3 months of maximal androgen deprivation (MAD)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: 6 months of maximal androgen deprivation (MAD)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: 0 months of maximal androgen deprivation (MAD)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Control group (no MAD)
Number of subjects: 818
Study: 12009244

Group type: EXPERIMENTAL
Intervention: VIP regimen (vindesine 3 mg/m² on days 1 and 8, ifosfamide 1300 mg/m² on days 1-5, cisplatin 20 mg/m² on days 1-5)
Number of subjects: 132

Group type: COMPARATOR
Intervention: VP regimen (vindesine and cisplatin with the same dose and schedule as VIP)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: VIP regimen
Number of subjects: 132

Group type: COMPARATOR
Intervention: VP regimen
Number of subjects: 132
Study: 10047931

Group type: EXPERIMENTAL
Intervention: Rimantadine at doses of 100 to 300 mg/d
Number of subjects: 14
Study: 7497673

Group type: EXPERIMENTAL
Intervention: Direct current
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Capacitive coupled electrical stimulation
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Bone graft surgery
Number of subjects: 271
Study: 2022202

Group type: EXPERIMENTAL
Intervention: Cold stress (cryotherapy)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cold stress (cold immersion)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (air at neutral temperatures)
Number of subjects: 7
Study: 6972449

Group type: EXPERIMENTAL
Intervention: Ampullometrogram (AMG) in patients with normal CMG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ampullometrogram (AMG) in patients with hyporeflexic CMG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ampullometrogram (AMG) in patients with hyperreflexic CMG
Number of subjects: 20
Study: 31081862

Group type: EXPERIMENTAL
Intervention: Intensive treatment (systolic blood pressure target of 110-139 mm Hg)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Standard treatment (systolic blood pressure target of 140-179 mm Hg)
Number of subjects: 870
Study: 28088223

Group type: EXPERIMENTAL
Intervention: Early integrated treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 50
Study: 25305506

Group type: EXPERIMENTAL
Intervention: MMR-proficient tumors with BRAF(V600E) mutations
Number of subjects: 2720

Group type: EXPERIMENTAL
Intervention: MMR-proficient tumors with KRAS mutations
Number of subjects: 2720

Group type: COMPARATOR
Intervention: MMR-deficient sporadic or familial subtypes
Number of subjects: 2720

Group type: COMPARATOR
Intervention: MMR-proficient tumors without BRAF(V600E) or KRAS mutations
Number of subjects: 2720
Study: 24079817

Group type: EXPERIMENTAL
Intervention: Aqueous intranasal corticosteroid (INS) formulation
Number of subjects: 185

Group type: COMPARATOR
Intervention: Aerosol intranasal corticosteroid (INS) formulation
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) scale
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction subscales
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Health-related quality of life scales
Number of subjects: 185
Study: 21865946

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (CRT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog mutation
Number of subjects: 132

Group type: COMPARATOR
Intervention: cyclin D1 G870A (AA) polymorphism
Number of subjects: 132

Group type: COMPARATOR
Intervention: methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism
Number of subjects: 132

Group type: COMPARATOR
Intervention: Combination of p53 and v-Ki-ras2 mutations
Number of subjects: 132

Group type: COMPARATOR
Intervention: Combination of p53 and either v-Ki-ras2 mutation or cyclin D1 G870A (AA) polymorphism or methylenetetrahydrofolate reductase (NAD(P)H) C677T (TT) polymorphism
Number of subjects: 132

Group type: COMPARATOR
Intervention: Biomarker combinations
Number of subjects: 132
Study: 19262477

Group type: EXPERIMENTAL
Intervention: Olmesartan + Calcium Channel Blocker (ARB/CCB group)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Olmesartan + Diuretic (ARB/diuretic group)
Number of subjects: 4000
Study: 16752259

Group type: EXPERIMENTAL
Intervention: Laparoscopic supravaginal hysterectomy (LSH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Abdominal supravaginal hysterectomy (ASH)
Number of subjects: 47
Study: 15209599

Group type: EXPERIMENTAL
Intervention: Intervention for patients presenting with physical symptoms
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intervention for patients presenting with psychological symptoms
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care for patients presenting with physical symptoms
Number of subjects: 200
Study: 11737955

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (100 mg dl-alpha-tocopheryl acetate, 200 mg ascorbic acid, 2 mg beta-carotene)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9442997

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behaviour Scales and EASE
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Informant differences
Number of subjects: 43
Study: 8112368

Group type: EXPERIMENTAL
Intervention: Didanosine as a single agent
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Didanosine with metoclopramide (10 mg IV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Didanosine with loperamide (4 doses of 4 mg each)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Didanosine with metoclopramide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Didanosine with loperamide
Number of subjects: 12
Study: 3803193

Group type: EXPERIMENTAL
Intervention: Telephone interviewing using the randomized response technique (RRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct questioning
Number of subjects: 0
Study: 30796122

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30187864

Group type: EXPERIMENTAL
Intervention: A/BPO‐EoN
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: A/BPO‐moisturizer
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups (A/BPO regimens)
Number of subjects: 120
Study: 27640067

Group type: EXPERIMENTAL
Intervention: 30 mg SCH 527123
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 23872939

Group type: EXPERIMENTAL
Intervention: Exercise (EX) - one 60-min bout at 60%-75% of heart rate reserve performed before breakfast
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sedentary (SED)
Number of subjects: 9
Study: 22119219

Group type: EXPERIMENTAL
Intervention: 2-L PEG+ascorbic acid
Number of subjects: 339

Group type: COMPARATOR
Intervention: 4-L PEG
Number of subjects: 339
Study: 20102922

Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg once per day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metoprolol 100 mg once per day
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 16
Study: 18929024

Group type: EXPERIMENTAL
Intervention: TopChair (stair-climbing power wheelchair)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Storm3 (conventional power wheelchair)
Number of subjects: 25
Study: 15823184

Group type: EXPERIMENTAL
Intervention: Combination of beclomethasone dipropionate 250 microg b.i.d and slow-release theophylline 0.2 g b.i.d (SRT/BDP group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 500 microg b.i.d (BDP group)
Number of subjects: 41
Study: 11952058

Group type: EXPERIMENTAL
Intervention: 90 dBA intermittent and unpredictable sound-burst condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: 50 dBA white noise condition
Number of subjects: 20
Study: 10614676

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous combined 2 mg estradiol and 1 mg norethisterone acetate (E+NETA) daily
Number of subjects: 100
Study: 8540760

Group type: EXPERIMENTAL
Intervention: Zidovudine 50 mg, 100 mg, 200 mg combined with Didanosine 67 mg, 167 mg, 250 mg
Number of subjects: 11
Study: 1784148

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (specific drugs not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digitized images for quantification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classical color models
Number of subjects: 0
Study: 7092500

Group type: EXPERIMENTAL
Intervention: Schedule for Affective Disorders and Schizophrenia‐Lifetime (SADS‐L)
Number of subjects: 42

Group type: COMPARATOR
Intervention: National Institute for Mental Health Diagnostic Interview Schedule (NIMH‐DIS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Comparison of SADS‐L and NIMH‐DIS
Number of subjects: 42
Study: 30840551

Group type: EXPERIMENTAL
Intervention: TLC‐NOSF dressing with poly‐absorbent fibres
Number of subjects: 88
Study: 27356944

Group type: EXPERIMENTAL
Intervention: Backward walking training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Forward walking training
Number of subjects: 30
Study: 27730198

Group type: EXPERIMENTAL
Intervention: Umeclidinium 62.5 µg
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Glycopyrronium 50 µg
Number of subjects: 1037
Study: 24284985

Group type: EXPERIMENTAL
Intervention: 5% cis-urocanic acid emulsion cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control vehicle
Number of subjects: 45
Study: 23126345

Group type: EXPERIMENTAL
Intervention: Automated blood pressure measurement device
Number of subjects: 225

Group type: COMPARATOR
Intervention: Manual blood pressure measurement device
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Consecutive visits (3 visits)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Consecutive visits (7 visits)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Consecutive visits (18 visits)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 7 visits spread over 4 years
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Single blood pressure measurement per visit
Number of subjects: 225
Study: 19156355

Group type: EXPERIMENTAL
Intervention: Atomoxetine (up to 1.2 mg/kg/day or 80 mg/day) with psychoeducation
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo with psychoeducation
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Atomoxetine (with psychoeducation)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (with psychoeducation)
Number of subjects: 99
Study: 18087899

Group type: EXPERIMENTAL
Intervention: Bromocriptine/evening primrose
Number of subjects: 80

Group type: COMPARATOR
Intervention: Low Intensity Laser Therapy (LILT)
Number of subjects: 80
Study: 16023298

Group type: EXPERIMENTAL
Intervention: Biobrane
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duoderm
Number of subjects: 0
Study: 12616983

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive preparations (30 micrograms ethinylestradiol with either 75 micrograms gestodene or 150 micrograms desogestrel)
Number of subjects: 77

Group type: COMPARATOR
Intervention: 17 beta-oestradiol (2 mg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive preparations (30 micrograms ethinylestradiol)
Number of subjects: 77
Study: 10721054

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8819814

Group type: EXPERIMENTAL
Intervention: Flecainide 150‐300 mg/die
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Propafenone 450‐900 mg/die
Number of subjects: 170

Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 170

Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 170
Study: 2048373

Group type: EXPERIMENTAL
Intervention: Meditation (N = 5)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Meditation and imagery (N = 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waiting list (N = 5)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment control group (N = 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Assessment control group during baseline periods (N = 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Psychological stress (prospective control group)
Number of subjects: 18
Study: 6127888

Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study: 31755559

Group type: EXPERIMENTAL
Intervention: Bilateral uterine artery ligation (BUAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (cesarean delivery without BUAL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BUAL and Control
Number of subjects: 0
Study: 28752645

Group type: EXPERIMENTAL
Intervention: High pressure (-150 mmHg)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Low pressure (-100 mmHg)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 164
Study: 26395743

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) including weight loss and physical activity
Number of subjects: 3845

Group type: COMPARATOR
Intervention: Diabetes support and education (Control)
Number of subjects: 3845
Study: 24944131

Group type: EXPERIMENTAL
Intervention: Football training group (FTG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 41
Study: 22525561

Group type: EXPERIMENTAL
Intervention: Early endoscopic treatment within 72 hours after initial symptom
Number of subjects: 120

Group type: COMPARATOR
Intervention: No endoscopic treatment (control group)
Number of subjects: 120
Study: 20389025

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of insulin (0.1 IU/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls (n = 9)
Number of subjects: 18
Study: 18710631

Group type: EXPERIMENTAL
Intervention: Inh‐Ins
Number of subjects: 253

Group type: COMPARATOR
Intervention: RI
Number of subjects: 253
Study: 16834579

Group type: EXPERIMENTAL
Intervention: New admission form
Number of subjects: 100

Group type: COMPARATOR
Intervention: Old admission form
Number of subjects: 100
Study: 12865040

Group type: COMPARATOR
Intervention: Healthy Lifestyle Control
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Dietary Weight Loss
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Structured Exercise
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Combined Exercise and Dietary Weight Loss
Number of subjects: 316
Study: 11100339

Group type: EXPERIMENTAL
Intervention: Octreotide (n = 58)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus octreotide (n = 44)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Sclerotherapy (n = 53 for group I; n = 42 for group II)
Number of subjects: 197
Study: 8896140

Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy followed by cystectomy
Number of subjects: 0
Study: 1667298

Group type: EXPERIMENTAL
Intervention: High-fibre diet
Number of subjects: 72
Study: 7071350

Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (80 mg/kg)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Intramuscular preparation (AMPS: atropine, meperidine, promethazine, secobarbital)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Endotracheal anesthesia
Number of subjects: 582

Group type: COMPARATOR
Intervention: General anesthesia (not specified)
Number of subjects: 582
Study: 31286116

Group type: EXPERIMENTAL
Intervention: One Shape
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Revo‐S
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: WaveOne
Number of subjects: 99
Study: 27822851

Group type: EXPERIMENTAL
Intervention: Vibrating-mesh nebulizer combined with a valved holding chamber (Aerogen Ultra®, Aerogen Ltd., Galway, Ireland)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Jet nebulizer connected to a corrugated tube (Opti‐Mist Plus Nebulizer®, ConvaTec, Bridgewater, NJ)
Number of subjects: 6
Study: 26203171

Group type: EXPERIMENTAL
Intervention: School-based drug-treatment and health-education intervention
Number of subjects: 75
Study: 24063287

Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lecture-Based Learning (LBL)
Number of subjects: 0
Study: 21931871

Group type: EXPERIMENTAL
Intervention: Long-lasting insecticidal nets (LNs)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (no LNs)
Number of subjects: 305
Study: 19525621

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: HAART after IPT
Number of subjects: 2778

Group type: COMPARATOR
Intervention: No IPT or HAART
Number of subjects: 2778

Group type: COMPARATOR
Intervention: HAART without IPT
Number of subjects: 2778

Group type: COMPARATOR
Intervention: IPT without HAART
Number of subjects: 2778
Study: 17192324

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (2-4 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (high-dose 8 mg/day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 78
Study: 15051570

Group type: EXPERIMENTAL
Intervention: Immunoblotting
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 44
Study: 11170976

Group type: EXPERIMENTAL
Intervention: oseltamivir
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 54
Study: 9571357

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 164
Study: 7846291

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment alongside practical care, initiated during pregnancy and conducted in mothers' homes on a long-term basis.
Number of subjects: 2
Study: 3044800

Group type: EXPERIMENTAL
Intervention: MP
Number of subjects: 320

Group type: COMPARATOR
Intervention: VCMP
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Maintenance treatment (induction scheme q 8 weeks)
Number of subjects: 320

Group type: COMPARATOR
Intervention: No further chemotherapy
Number of subjects: 320
Study: 31466276

Group type: EXPERIMENTAL
Intervention: Supervised controlled exercise at 8 kcal/kg of body weight/week
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Supervised controlled exercise at 20 kcal/kg of body weight/week
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study: 28783872

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF) 240 mg twice daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 46
Study: 25557985

Group type: EXPERIMENTAL
Intervention: BoNT‐A injected at MEP zones (30% and 60% of the distance from the pubic tubercle to the medial epicondyle)
Number of subjects: 27

Group type: COMPARATOR
Intervention: BoNT‐A injected proximally (25% of the distance from the pubic tubercle to the medial epicondyle)
Number of subjects: 27
Study: 24029542

Group type: EXPERIMENTAL
Intervention: Warfarin dosing algorithm with daily INR measurements
Number of subjects: 30
Study: 21675334

Group type: EXPERIMENTAL
Intervention: Occupational Goal Intervention (OGI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Frontal Executive Program
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 19465443

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 microg IM once weekly
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a 30 microg IM once weekly plus AZA 50 mg orally once daily plus prednisone 10 mg orally every other day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a plus AZA
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a plus AZA and prednisone
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a alone
Number of subjects: 181
Study: 16445446

Group type: EXPERIMENTAL
Intervention: AcrySof Natural (SN60AT) IOL
Number of subjects: 19

Group type: COMPARATOR
Intervention: AcrySof single‐piece (SA60AT) IOL
Number of subjects: 19
Study: 15031241

Group type: EXPERIMENTAL
Intervention: Minimum criterion based model
Number of subjects: 66

Group type: COMPARATOR
Intervention: Educational outcome model
Number of subjects: 66
Study: 11567748

Group type: EXPERIMENTAL
Intervention: Low-dose diphtheria-tetanus vaccine (dT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard paediatric dose (DT)
Number of subjects: 0
Study: 9562691

Group type: EXPERIMENTAL
Intervention: AZT and VaxSyn
Number of subjects: 30

Group type: COMPARATOR
Intervention: VaxSyn
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AZT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IL-2 in vitro
Number of subjects: 30
Study: 7843201

Group type: EXPERIMENTAL
Intervention: Single or multiple doses of natural porcine surfactant (Curosurf)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Single-dose surfactant treatment
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Multiple-dose surfactant treatment
Number of subjects: 343
Study: 2894548

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 16